A pivotal registrational trial of Vascepa® (icosapent ethyl) capsules in a patient population with severe hypertriglyceridemia

Next Previous
Trial Profile

A pivotal registrational trial of Vascepa® (icosapent ethyl) capsules in a patient population with severe hypertriglyceridemia

Recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Jan 2018

At a glance

  • Drugs Ethyl eicosapentaenoic acid (Primary)
  • Indications Hypertriglyceridaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Amarin Corporation

    • Most Recent Events

    • 18 Jan 2018 New trial record
    • 17 Jan 2018 According to an Amarin Corporation media release, Eddingpharm anticipates that the study will be completed within the next two years.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top